Intrathecal serotherapy in neonatal tetanus: a controlled trial

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• Neonatal tetanus poses a significant mortality risk in infants.
• Tetanus antitoxin (TAT) is a standard treatment, but its efficacy can be enhanced.
• The role of intrathecal administration of human tetanus immune globulin (TIG) alongside TAT requires further investigation.

Purpose of the Study:

• To compare the efficacy of equine tetanus antitoxin (TAT) alone versus TAT combined with intrathecal human tetanus immune globulin (TIG) in treating neonatal tetanus.

Main Methods:

• A randomized controlled trial involving 60 infants diagnosed with neonatal tetanus.
• Infants were assigned to two groups: Group 1 received 40,000 units of equine TAT (IV and IM). Group 2 received 40,000 units of equine TAT (IV and IM) plus 150 units of TIG intrathecally.
• Infants in both groups were similar regarding age, sex, weight, incubation period, temperature, and clinical presentation.

Main Results:

• There were no statistically significant differences in mortality rates between the two treatment groups.
• The duration of hospitalization and the number of days requiring sedation were also comparable in both groups.
• These findings suggest that adding intrathecal TIG to standard TAT treatment did not yield superior clinical outcomes.

Conclusions:

• Intrathecal administration of human tetanus immune globulin (TIG) in addition to equine tetanus antitoxin (TAT) does not significantly improve outcomes for infants with neonatal tetanus.
• Standard equine tetanus antitoxin (TAT) treatment appears sufficient, showing comparable efficacy to combined therapy in this study population.
• Further research may explore alternative strategies or dosages if enhanced protection is sought in severe neonatal tetanus cases.